Last reviewed · How we verify
empagliflozin 10mg
At a glance
| Generic name | empagliflozin 10mg |
|---|---|
| Also known as | Empamax 10mg, EMPA |
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism (PHASE2)
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension (PHASE4)
- CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients (PHASE2)
- Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease (EARLY_PHASE1)
- Empagliflozin Reversal of Arterial StiffnEss in Aging (PHASE2, PHASE3)
- Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients (PHASE4)
- Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- empagliflozin 10mg CI brief — competitive landscape report
- empagliflozin 10mg updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI